<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05014490</url>
  </required_header>
  <id_info>
    <org_study_id>ETR01-E</org_study_id>
    <nct_id>NCT05014490</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Test and Reference 120 mg Etoricoxib Film-coated Tablets in Healthy Volunteers</brief_title>
  <official_title>Randomized, Open-label, Single-dose, Two-sequence, Two-period, Crossover, Comparative, Oral Bioequivalence Study of Exib 120 mg Etoricoxib Film-coated Tablets (PrJSC &quot;Pharmaceutical Firm &quot;Darnitsa&quot;) and Arcoxia 120 mg Etoricoxib Film-coated Tablets (Merck Sharp&amp;Dohme B.V.) in Healthy, Adult Volunteers Under Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Darnitsa Pharmaceutical Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Anapharm Bioanalytics</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Darnitsa Pharmaceutical Company</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study is a comparative bioavailability study performed to assess bioequivalence&#xD;
      between a Test medication (Exib 120 mg etoricoxib film-coated tablets manufactured by PrJSC&#xD;
      &quot;Pharmaceutical firm &quot;Darnitsa&quot; [Ukraine]) and a Reference medication (marketed medicinal&#xD;
      product Arcoxia® 120 mg etoricoxib film-coated tablets, Marketing Authorisation Holder: UAB&#xD;
      &quot;Merck Sharp&amp;Dohme&quot;, Lithuania) in healthy volunteers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 24, 2021</start_date>
  <completion_date type="Actual">March 24, 2021</completion_date>
  <primary_completion_date type="Actual">March 24, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Two-period, two-sequence, two-way crossover single dose study</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum plasma concentration (Cmax)</measure>
    <time_frame>Blood sampling for pharmacokinetic analysis covered up to 72 hours post-dose.</time_frame>
    <description>The Cmax values are based on the etoricoxib plasma concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve from time zero to the last quantifiable concentration (AUC0-t)</measure>
    <time_frame>Blood sampling for pharmacokinetic analysis covered up to 72 hours post-dose.</time_frame>
    <description>The AUC0-t is the area under the plasma concentration versus time curve from time zero (predose) to time of last quantifiable concentration (t) and is based on the etoricoxib plasma concentration.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Bioequivalence</condition>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Exib (Test)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single oral dose of the test product Exib 120 mg etoricoxib film-coated tablets.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arcoxia® (Reference)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A single oral dose of the reference product Arcoxia® 120 mg etoricoxib film-coated tablets.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exib 120 mg etoricoxib film-coated tablets</intervention_name>
    <description>Oral, COX-2 highly selective, non-steroidal anti-inflammatory generic drug</description>
    <arm_group_label>Exib (Test)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arcoxia® 120 mg etoricoxib film-coated tablets</intervention_name>
    <description>Oral, COX-2 highly selective, non-steroidal anti-inflammatory innovative drug</description>
    <arm_group_label>Arcoxia® (Reference)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Caucasian males.&#xD;
&#xD;
          2. Subjects aged between 18 and 55 years (inclusively) at the date of signing ICF which&#xD;
             was defined as the beginning of the screening period.&#xD;
&#xD;
          3. Subjects with a BMI at screening within 18.5 to 30.0 kg/m2, inclusively.&#xD;
&#xD;
          4. Willingness to adhere to the protocol requirements and to provide written, personally&#xD;
             signed, and dated ICF to participate in the study before the start of any&#xD;
             study-related procedures.&#xD;
&#xD;
          5. Availability for the entire duration of the study.&#xD;
&#xD;
          6. Motivated subjects with absence of intellectual problems likely to limit the validity&#xD;
             of consent to participate in the study or the compliance with protocol requirements;&#xD;
             ability to cooperate adequately; ability to understand and observe the instructions of&#xD;
             the physician or designee.&#xD;
&#xD;
          7. Satisfactory medical assessment at screening with no clinically relevant abnormalities&#xD;
             as determined by medical history, physical examination, ECG, and clinical laboratory&#xD;
             evaluation (haematology, biochemistry and urinalysis) that were reasonably likely to&#xD;
             interfere with the subject's participation in or ability to complete the study as&#xD;
             assessed by the Investigator.&#xD;
&#xD;
          8. Subjects were required to agree to abstain from xanthine-containing products (i.e.&#xD;
             coffee, tea, cola, energy drinks, chocolate, etc.) from 48 hours prior to the first&#xD;
             study drug administration until the end of confinement.&#xD;
&#xD;
          9. Subjects were required to agree to abstain from poppy seed-containing products from 48&#xD;
             hours prior to the first study drug administration until the end of confinement.&#xD;
&#xD;
         10. Subjects were required to agree to abstain from alcohol from 48 hours prior to the&#xD;
             first study drug administration until the end of study.&#xD;
&#xD;
         11. Subjects were required to abstain and agree to continue to abstain from St John's&#xD;
             Wort, vitamins and herbal remedies from 2 weeks prior to the first study drug&#xD;
             administration until the end of confinement.&#xD;
&#xD;
         12. Subjects were required to abstain and agree to continue to abstain from beverages or&#xD;
             food containing orange, grapefruit or pomelo from 2 weeks prior to the first study&#xD;
             drug administration until the end of confinement.&#xD;
&#xD;
         13. Subjects had to agree to use medically acceptable methods of contraception during the&#xD;
             study and for 30 days after the end of the study. Medically acceptable methods of&#xD;
             contraception included using a condom with a female partner of childbearing potential&#xD;
             who is using oral contraceptives, hormonal patch, implant or injection, intrauterine&#xD;
             device, or diaphragm with spermicide. Complete abstinence alone could be used as a&#xD;
             method of contraception.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of significant hypersensitivity to etoricoxib or any related products&#xD;
             (including excipients of the formulations) as well as severe hypersensitivity&#xD;
             reactions (such as angioedema) to any drug.&#xD;
&#xD;
          2. Presence of significant gastrointestinal, liver or kidney disease, or any other&#xD;
             conditions known to interfere with the absorption, distribution, metabolism or&#xD;
             excretion of drugs or known to potentiate or predispose to undesired effects.&#xD;
&#xD;
          3. History of major surgery of the gastrointestinal tract except for appendectomy.&#xD;
&#xD;
          4. History of significant gastrointestinal, liver or kidney disease that might affect the&#xD;
             drug BA.&#xD;
&#xD;
          5. Presence of significant cardiovascular, respiratory, genitourinary, musculoskeletal,&#xD;
             hematologic, neurological, psychiatric, endocrine, immunologic or dermatologic&#xD;
             disease.&#xD;
&#xD;
          6. Presence of respiratory infection symptoms (COVID-19 infection symptoms) like fever,&#xD;
             dry cough, nasal congestion or sore throat.&#xD;
&#xD;
          7. Having COVID-19 infection or having been in contact to people with known COVID-19&#xD;
             infection in the last 14 days.&#xD;
&#xD;
          8. Use of tobacco in any form (e.g., smoking or chewing) or other nicotine-containing&#xD;
             products in any form (e.g., gum, patch, electronic cigarettes) within 6 months prior&#xD;
             to Day 1 Period 1.&#xD;
&#xD;
          9. History of controlled or uncontrolled hypertension or clinically relevant Systolic&#xD;
             Blood Pressure (SBP), Diastolic Blood Pressure (DBP) and/or Heart Rate (HR) readings&#xD;
             outside the normal ranges at screening (Day -3) or prior to drug administration on Day&#xD;
             1 Period 1. Normal ranges are defined below:&#xD;
&#xD;
               -  SBP: 90 to 140 mmHg&#xD;
&#xD;
               -  DBP: 60 to 90 mmHg&#xD;
&#xD;
               -  HR: 50 to 100 beats/min&#xD;
&#xD;
         10. Forehead body temperature readings outside the range of 35.5 to 37.4 ºC at screening&#xD;
             (Day -5, -4, -3, -2, -1) or prior to the first drug administration.&#xD;
&#xD;
         11. Any planned surgery involving general, spinal or epidural anaesthesia from 3 months&#xD;
             prior to Day 1 Period 1 to 7 days after last dosing.&#xD;
&#xD;
         12. Known presence of rare hereditary problems of galactose and/or lactose intolerance,&#xD;
             lactase deficiency or glucose-galactose malabsorption.&#xD;
&#xD;
         13. Any clinically significant illness within 30 days prior to Day 1 Period 1.&#xD;
&#xD;
         14. Use of any enzyme-modifying drugs, including strong inhibitors of cytochrome P450&#xD;
             (CYP) enzymes (such as cimetidine, fluoxetine, quinidine, erythromycin, ciprofloxacin,&#xD;
             fluconazole, ketoconazole, diltiazem and Human Immunodeficiency Virus (HIV)&#xD;
             antivirals) and strong inducers of CYP enzymes (such as barbiturates, carbamazepine,&#xD;
             glucocorticoids, phenytoin and rifampicin) within 30 days prior to Day 1 Period 1.&#xD;
&#xD;
         15. Use of Over the Counter (OTC) medications within 7 days prior to Day 1 Period 1. It&#xD;
             was specifically reminded that this included cold preparations, Acetylsalicylic Acid&#xD;
             (ASA), natural products used for therapeutic benefits and antacid preparations.&#xD;
&#xD;
         16. Intake of any prescription medication within 30 days prior to Day 1 Period 1.&#xD;
&#xD;
         17. Maintenance therapy with any drug or significant history of drug dependency.&#xD;
&#xD;
         18. Alcohol abuse, i.e. regular use of more than 10 units per week (one unit of alcohol&#xD;
             equals 250 mL of beer, 125 mL of wine or 25 mL of spirits), a history of alcoholism or&#xD;
             recovered alcoholics.&#xD;
&#xD;
         19. Positive alcohol, drugs of abuse or cotinine results at screening (Day -1).&#xD;
&#xD;
         20. Positive result on Day -5 and/or Day -2 of screening on COVID-19 RT-PCR test.&#xD;
&#xD;
         21. History of drug abuse or use of illegal drugs: use of soft drugs (e.g. marihuana)&#xD;
             within 6 months of screening or hard drugs (e.g. amphetamines, barbiturates,&#xD;
             benzodiazepines, cannabinoids, cocaine and opioids) within 1 year of screening.&#xD;
&#xD;
         22. A positive Human Immunodeficiency Virus antibody (HIV-Ab) screen, Hepatitis B surface&#xD;
             antigen (HBsAg) or Hepatitis C Virus (HCV) tests.&#xD;
&#xD;
         23. Use of an investigational product within 60 days prior to Day 1 Period 1 or active&#xD;
             enrolment in another drug or vaccine clinical study.&#xD;
&#xD;
         24. Use of depot injectable solutions with a half-life of &gt;1 week within 6 months prior to&#xD;
             Day 1 Period 1.&#xD;
&#xD;
         25. Subjects previously randomised in this study.&#xD;
&#xD;
         26. An inability to follow a standardised diet and meal schedule or inability to fast, as&#xD;
             required during the study.&#xD;
&#xD;
         27. Donation of blood (at least 100 mL) or plasma by plasmapheresis within 30 days prior&#xD;
             to Day 1 Period 1.&#xD;
&#xD;
         28. Volunteers who reported difficulty swallowing tablets as a whole.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Erciyes University Hakan Çetinsaya İyi Klinik Uygulama ve Arastirma Merkezi, IKUM (Center for GCP)</name>
      <address>
        <city>Kayseri</city>
        <zip>38038</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 3, 2021</study_first_submitted>
  <study_first_submitted_qc>August 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2021</study_first_posted>
  <last_update_submitted>August 13, 2021</last_update_submitted>
  <last_update_submitted_qc>August 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>bioequivalence</keyword>
  <keyword>etoricoxib</keyword>
  <keyword>healthy subjects</keyword>
  <keyword>pharmacokinetics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etoricoxib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

